Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMN8QAF)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Hexamethonium; hexamethonium; Hexonium; Benzohexamethonium; Hexamethonum; Bistrium; Hexanium; 60-26-4; UNII-3C9PSP36Z2; Esametonio [Italian]; CHEMBL100622; CHEBI:5700; 3C9PSP36Z2; N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium; NCGC00163239-01; Hexane-1,6-bis(trimethylammonium); 1,6-Hexanediaminium, N,N,N,N',N',N'-hexamethyl-; DSSTox_RID_80651; DSSTox_CID_25053; DSSTox_GSID_45053; BRN 1760389; Esametonio; CHEMBL332524; CAS-60-26-4; Hexamethonium [INN]; Ammonium, hexamethylenebis(trimethyl-; trimethyl-[6-(trimethylazaniumyl)hexyl]azanium
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||
